Sep 10, 2021
MediSieve Visits MyBiotech
MyBiotech GmbH is MediSieve's production partner, collaborating with the company to validate the manufacture of the Beads.
MyBiotech GmbH is MediSieve's production partner, collaborating with the company to validate the manufacture of the Beads. MyBiotech offers end to end development, manufacturing services and innovative products for biotech and pharma companies. The company has an established network and a team made up of experts, offering their help and knowledge to numerous international companies.
MediSieve's CTO Cristina Blanco - Andujar has commented on the visit:
"Thanks to the ease of the travel restrictions, we were finally able to visit MyBiotech in person. This visit has provided a unique opportunity for MediSieve to get a deep understanding of the capabilities and infrastructure at MyBiotech, but more importantly, it has created the space to strengthen the relationship between the companies and ensure the alignment in our vision towards a long term relationship."
MediSieve is delighted to be working with MyBiotech and is eagerly looking forward to the results. Hopefully, the in person visits will become more frequent as a change of environment always helps to come up with new solutions to problems.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: